Congenital erythropoietic porphyria (CEP) is a rare autosomal recessive disorder of porphyrin metabolism in which the genetic defect is the deficiency of uroporphyrinogen III cosynthase (UIIIC). Deficiency of this enzyme results in an accumulation of high amounts of uroporphyrin I in all tissues leading to hemolytic anemia, splenomegaly, erythrodontia, bone fragility, exquisite photosensitivity and mutilating skin lesions. We describe the case of a 23-month-old boy who was cured of his CEP by a matched-sibling allogeneic bone marrow transplant, and review the published clinical experience regarding transplantation in this disease. He is alive and disease-free 15 months post transplant. All of his disease manifestations except for the erythrodontia have resolved. His UIIIC level and stool and erythrocyte porphyrin metabolites have almost completely corrected. He is the sixth child reported to be cured of this disease by stem cell transplantation, five cases being long-term survivors. If patients with this disease have an HLA-matched sibling, then stem cell transplantation should be strongly considered because this is currently the only known curative therapy. Bone Marrow Transplantation (2001) 27, 101-105. Keywords: congenital erythropoietic porphyria; porphyria; stem cell transplantation; bone marrow transplantation Congenital erythropietic porphyria (CEP), or Gunther's disease, is one of the rarest of the porphyrias, a group of metabolic disorders in which excessive quantities of porphyrins or their precursors are produced. This autosomal recessive disorder is caused by a defect of the enzyme uroporphyrinogen III cosynthase (UIIIC) that leads to an accumulation of uroporphyrinogen I and coproporphyrinogen I in all tissues. The primary clinical manifestations of this accumulation include erythrodontia, bone fragility, hypertrichosis,
ocular complications, hemolytic anemia and extreme photosensitivity which results in mutilating scarring. The anemia may be severe enough to require chronic transfusion. As a result of the ravages of this disease, people who have it historically have a shorter life expectancy.
Many modalities have been used to treat this disease with temporary, if any, effect because they are supportive and do not address the primary cause of the disease, the deficiency of uroporphyrinogen III cosynthase. Thus far, stem cell transplantation (SCT) is the only curative therapy for CEP. It is effective because the transplanted stem cells produce normal levels of UIIIC and reverse the disease manifestations. Five reports of children with CEP treated with SCT have been published worldwide, four of them being long-term survivors with abatement of disease manifestations. [25] [26] [27] [28] [29] We report the successful treatment of CEP in a 23-month-old boy by allogeneic bone marrow transplantation (BMT) from a matched-sibling donor.
Case report

Clinical history
A boy of Palestinian descent who was full-term was born vaginally without complications. During his first month of life, he was found to have pink urine. He was evaluated by a pediatric nephrologist who found no abnormalities. When his teeth began to erupt, they were noted to be dark blue. As the patient became more active, his parents noticed that cuts and bruises on his face and limbs required several weeks to heal.
At the age of 15 months, during a visit to Israel, he was exposed to the sun and exposed areas of his skin began to erupt into large vesicles. These lesions healed poorly, became easily infected and formed large scars. He was suspected of having erythropoietic porphyria and sent to the United States for confirmation of the diagnosis.
The family medical history was significant for two firstdegree cousins with beta-thalassemia. There was no family history of porphyria and no consanguinity. His parents were unrelated Lebanese Muslims from different regions of Israel and he had two healthy sisters aged 4 and 6 years.
On examination he was noted to have areas of hypo- and hyperpigmentation over his face and extremities with multiple poorly healed crusted lesions over these areas and a few intact tiny vesicles ( Figure 1 ). His skin was also significant for hypertrichosis over his forehead and temples. His teeth were well developed but dark blue ( Figure 2 ). Wood's lamp examination of his teeth, urine and sclerae revealed red-orange fluorescence. His splenic tip was palpable 3 cm below the left costal margin but he had no hepatomegaly. His urine was pink in appearance and urinalysis demonstrated hemoglobinuria and trace protein. His laboratory investigations were remarkable for a hemoglobin (Hb) of 9.4 g/dl, a reticulocyte count of 4%, a zinc protoporphyrin (ZPP) level of 670 mol/mol Hb (normal 30-70) and a lactic dehydrogenase (LDH) of 644 IU/l (normal 221-473). His erythrocyte, urine and fecal porphyrin levels were all significantly elevated while his erythrocyte uroporphyrinogen III cosynthase level was low (Table 1) . These laboratory findings, in conjunction with his history and physical examination were diagnostic of CEP. The patient and his family were HLA-typed. While awaiting these results, he was prescribed a zinc oxide-based sun protectant and was instructed to stay out of direct sunlight.
Figure 2
Red-blue discoloration of the teeth (erythrodontia).
Transplantation procedure
His older sister was an HLA-identical match, so at the age of 23 months he received a bone marrow transplant with this sister serving as the donor. The conditioning regimen consisted of busulfan 4 mg/kg i.v. in four divided doses daily from day −9 to day −6 (total dose 16 mg/kg) and cyclophosphamide 50 mg/kg once daily from day −5 to day −2 (total dose 200 mg/kg). He also received mesna 360 mg/m 2 i.v. on each day he received cyclophosphamide (total dose 1440 mg/m 2 ). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine 3 mg/kg i.v. in two divided doses daily beginning on day −1 and methotrexate 15 mg/m 2 i.v. once on day +1 and 10 mg/m 2 once daily on days +3 and +6. Granulocyte colony-stimulating factor (GCSF) 10 g/kg i.v. was given daily starting on day +7. Cytogam 100 mg/kg i.v. was administered weekly starting on day −1 and continued for 3 months and then monthly for 3 months. Pentamidine 4 mg/kg i.v. was given monthly starting day −1 as Pneumocystis carinii prophylaxis and continued until day +180.
Clinical course
The patient reached an absolute neutrophil count of 500/l on day +13, received his last platelet transfusion on day +11 and his last packed red blood cell transfusion on day +26 post transplant. He never manifested signs of GVHD. Variable-number tandem repeats (VNTR) at days +12 and +100 demonstrated 100% donor origin DNA consistent with full chimeric engraftment. The patient is currently 15 months post transplant and his skin lesions have completely healed. He no longer develops blisters or scars when exposed to direct sunlight. His hypertrichosis has also resolved. His urine is normal in color and unremarkable on urinalysis and on Wood's lamp examination. His hemoglobin is normal at 12 g/dl. His primary teeth remain dark blue in color and continue to fluoresce red-orange under the Wood's lamp. As prior to transplant, he remains developmentally appropriate and is a very verbal, engaging boy.
Stool and erythrocyte porphyrin levels and uroporphoryinogen III cosynthase levels were assessed prior to transplant, 7 months post transplant and 12 months post transplant. His fecal coproporphyrin I, fecal coproporphyrin III, erythrocyte protoporphyrin, erythrocyte coproporphyrin, erythrocyte uroporphyrin and erythrocyte uroporphyrinogen III cosynthase levels were almost completely corrected by 7 months post transplant and continued to be near normal at 12 months (Table 1 ). The only value to never completely normalize was fecal coproporphyrin I which reduced from 57 792 g/24 h to 888 g/24 h at 12 months. Urine porphyrin levels, which were assayed at diagnosis and found to be elevated (Quest Diagnostics, Teterboro, NJ, USA) were not examined after the transplant.
Discussion
Congenital erythropoietic porphyria was first described in 1874 when Schultz 30 wrote of a 33-year-old weaver who had had cutaneous photosensitivity since 3 months of age, splenomegaly, anemia and wine-colored urine. In 1911, it was described in greater detail by Gunther 31 and came to be known as Gunther's disease. It is one of the rarest of the porphyrias (less than 150 cases reported). Seen in all ethnic groups, Fritsch et al 1 catalogued all documented patients to 1994. This disease usually manifests in infancy or early childhood, although it can be diagnosed later in life.
The disease is the result of decreased activity of uroporphyrinogen III cosynthase, the fourth of eight enzymes along the pathway that produces heme from glycine and succinyl CoA. The substrate upon which this enzyme acts, hydroxymethylbilane (HMB) accumulates and condenses spontaneously to uroporphyrinogen I which in turn can be decarboxylated to coproporphyrinogen I. Both uroporphyrinogen I and coproporphyrinogen I accumulate in the bone marrow, erythrocytes, plasma, bones and teeth where they are metabolized to uroporphyrin I (a.k.a. urogen I) and coproporphyrin I (a.k.a. coprogen I) and are excreted in feces and urine. These porphyrins become excited by visible light (especially 400-410nm in wavelength) and emit a red fluorescence, as evidenced when our patient's teeth, sclerae and urine were exposed to a Wood's lamp. The energy released reacts with oxygen to produce free radicals that damage involved tissue.
Patients with CEP can have the worst skin manifestations of all the porphyrias due to the massive elevation of lipid soluble porphyrins, which deposit in the skin. This photosensitivity leads to phototoxic reactions and increased collagenase production resulting in second-or third-degree burns with vesicle and bullae formation. These become ulcerated, infected, require a prolonged period to heal and over time can lead to mutilations of the extremities and face. Nails and fingers may be lost. Hypopigmentation and Bone Marrow Transplantation hyperpigmentation are also evident in exposed areas and hypertrichosis is usually seen. Skeletal deposition leads to bone fragility. By adulthood, patients can develop severe osteolysis, resorption of the terminal phalanges, contractures and other bony deformities. Vitamin D deficiency from avoidance of sunlight may contribute to these abnormalities of bone structure. Ocular manifestations include conjunctivitis, blepharitis, photophobia, cataracts, corneal scarring and the loss of eyelashes and eyebrows. Porphyrin deposition in the sclerae leads to fluorescence with Wood's lamp exposure. Identical fluorescence occurs in the patients' teeth caused by deposition of porphyrins in dentine and enamel during tooth formation. When not under the Wood's lamp, the teeth appear blue or red-brown in color (erythrodontia).
Hematologic manifestations are also part of CEP's clinical presentation. Excessive porphyrins in erythrocytes results in fragility and osmotic hemolysis, which in turn leads to chronic hemolytic anemia and consequent splenomegaly. Hepatomegaly is also occasionally seen as a result of this. Because the heme synthesis pathway is disrupted, erythropoiesis is obviously less effective. As a result of this, ZPP is elevated and many nucleated red blood cells (which themselves are fluorescent) are prominent on a peripheral blood smear.
In addition to the pathognomonic clinical features of CEP, there are also characteristic laboratory findings. Uroporphyrinogen III cosynthase activity in erythrocytes is markedly decreased or absent. Elevated protoporphyrin levels are seen in erythrocytes and uroporphyrin I and coproporphyrin I levels are detectable in erythrocytes, plasma, urine and feces. Anemia, as mentioned above, is partially compensated by an elevated reticulocyte count. LDH is also elevated as an indicator of hemolysis. The splenomegaly of hemolytic anemia can lead to sequestration of platelets and thus a secondary thrombocytopenia.
All aspects of CEP make it a potentially devastating and deforming disease requiring some form of treatment. Therapeutic interventions in the past have included protection from sunlight (which is essential until definitive treatment is implemented), beta-carotene to reduce oxidative damage, 1,2 splenectomy to decrease anemia and thrombocytopenia, 1-12 transfusion regimens 13 and i.v. hematin (oxidized free heme) therapy 8, [14] [15] [16] to suppress hemoglobin production, adsorbents to bind to porphyrins and increase their excretion, 17, [20] [21] [22] hydroxyurea, 13, 23, 24 and steroids. 13, [17] [18] [19] [20] The most effective therapy would be one that increases uroporphyrinogen III cosynthase activity into the normal range, as it is reduced to 0 to 40% of normal in erythrocytes and fibroblasts of patients with CEP (approximately 50% of normal in carriers). Romeo and Levin 32 first identified this enzymatic deficiency in 1969, and as of 1998, 18 different mutations of chromosome 10 causing CEP had been described. 33 Knowing the location of a mutation makes gene therapy an attractive method of treatment, but although promising, this work is only in the pre-clinical stages. [33] [34] [35] Stem cell transplantation is another logical therapy because the UIIIC enzyme defect is present in red blood cells and fibroblast derivatives, all of which have a common stem cell ancestor. It is now known to be the only curative therapy for CEP. The first documented use of SCT for CEP was published by Kauffman et al in 1991. 25 Their patient, a 10-year-old girl fully engrafted and had improvement of her skin lesions but died of CMV pneumonitis 11 months post BMT. Zix-Kieffer et al 26 in 1995 reported a 4-yearold girl transplanted with her brother's HLA-identical cord blood. She was alive and disease-free 10 months later, with resolution of all disease manifestations including improvement in dental color. Soon after, Thomas et al 27 reported a 22-month-old girl transplanted for CEP who required a second infusion of donor bone marrow at 8 months after her first transplant when she had evidence of graft failure. She was completely asymptomatic 1 year after her second BMT. Her donor was a heterozygote with 50% enzyme activity, a level the patient attained after transplant. The fourth successful treatment of CEP was reported by Lagarde et al 28 when they described the treatment and course of a 2-year-old girl who was clinically well 21 months after her second BMT from the same BM source (a heterozygote sibling). As with Thomas' patient, she required a second infusion of bone marrow cells, in this case 8 months after the first. Both patients transplanted with marrow from HLA-identical heterozygotes produced approximately 50% of normal levels of UIIIC and had complete resolution of disease manifestations, demonstrating that using a matched sibling carrier as the stem cell source is still a good option. The fifth and most recent published case by Tezcan et al 29 described an 18-month-old transfusion-dependent girl who was cured of her CEP by allogeneic BMT and is alive and disease-free 3 years later.
Adding our patient to the collective experience brings the total number of published cases of CEP successfully treated with SCT to six ( Table 2) . Although this number is small, all children were effectively cured of their disease and had no clinically significant sequelae from their porphyria. As this treatment modality continues to be the only method of curing CEP, we suggest early transplantation in future cases if the patient has an HLA-identical sibling who is a carrier or is unaffected. If there are no adequate bone marrow donors available, unrelated umbilical cord blood may be a viable stem cell option for these patients, but this remains to be investigated.
